Surveillance imaging in mantle cell lymphoma in first remission lacks clinical utility.
Mantle cell lymphoma (MCL) is a heterogeneous disease with high relapse rates. Limited data guide the use of surveillance imaging following treatment. We constructed a retrospective cohort from two academic institutions of patients with MCL who completed first-line therapy and underwent follow-up for relapse, analyzing the effect of surveillance imaging on survival. Of 217 patients, 102 had documented relapse, with 38 (37%) diagnosed by surveillance imaging and 64 (63%) by other methods. Relapse diagnosis by surveillance imaging had no significant advantage in overall survival from diagnosis date (hazard ratio [HR] = 0.80, p = .39) or relapse date (HR = 0.72, p = .22). Of 801 surveillance images, PET/CT had a positive predictive value (PPV) of 24% and number needed-to-scan/treat (NNT) of 51 to detect one relapse, and CT had a PPV of 49% and NNT of 24. For MCL after first-line therapy, relapse detection by surveillance imaging was not associated with improved survival and lacks clinical benefit.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
DOI
EISSN
Publication Date
Volume
Issue
Start / End Page
Location
Related Subject Headings
- Survival Analysis
- Retrospective Studies
- Proportional Hazards Models
- Predictive Value of Tests
- Positron Emission Tomography Computed Tomography
- Neoplasm Recurrence, Local
- Middle Aged
- Male
- Lymphoma, Mantle-Cell
- Immunology
Citation
Published In
DOI
EISSN
Publication Date
Volume
Issue
Start / End Page
Location
Related Subject Headings
- Survival Analysis
- Retrospective Studies
- Proportional Hazards Models
- Predictive Value of Tests
- Positron Emission Tomography Computed Tomography
- Neoplasm Recurrence, Local
- Middle Aged
- Male
- Lymphoma, Mantle-Cell
- Immunology